×
aptamer@aptsci.com
031-786-0317
+82-31-786-0317
About Us
Overview
Vision
Key Executives
History
Company Identity
Location
About Aptamer
About Aptamer
Aptamer Discovery Technology
Aptamer Archive
Aptamer Services
Therapeutics
Discovery Platform
AlloMAp
BiFAp
Therapeutic Pipeline
Diagnosis
AptoMIA
Protein-Aptamer Binding Technique
Aptamer Quantitation Technique
Diagnosis Pipeline
AptoDetect™-Lung
Investing Information
Financial Information
Stock Information
News
Notice
Press Release
Patents
Publications
English
Korean
Therapeutic Aptamer
Discovery Platform
Home
Therapeutics
Therapeutic Pipeline
Discovery Platform
AlloMAp
BiFAp
Close
Therapeutic Pipeline
Pipeline
AlloMAp Platform Programs
Program
Indication
Discovery
Lead Optimization
Preclinical
Clinical
AST-101
T1DM/T2DM
AST-102
T2DM
BiFAp Platform Programs
Program
Indication
Discovery
Lead Optimization
Preclinical
Clinical
AST-201
Liver cancer
AST-202
AMD, DR
AST-203
GMB
AST-301
DM
AST-302
Parkinson’s disease
AST-101
Allosteric agonist aptamer to insulin receptor without side effects
- Low weight gain / Reduced CVD/cancer risks
- No insulin-induced insulin resistance
AST-101
AST-101 developmental status
- Selected “ Big Pharma Joint R&D Program “ and supported by Korea Drug Development Fund(KDDF)
· Discovery (KDDF201601-04)
· Preclinical (KDDF201809-05)
- 2020 4Q : IND filing & Phase I study
AST-102
Development of the insulin sensitizer with novel MoA
- Reduced risk of insulin-induced hypoglycemia
- Effective glycemic control by improving insulin sensitivity
AST-102
AST-102 developmental status
AST-201
Unmet needs for liver cancer
- Ranks 12
th
on Incidence rate, ranks 4
th
on mortality rate
- High unmet medical needs
AST-201
- GPC3-targeted BiFAp aptamer incorporated with gemcitabine
- Anti-cancer effect specific to GPC3-expressing hepatocellular carcinoma cells
AST-201 development status
TOP